Stocks · News reference
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).
Nautilus Biotechnology Files $300M Shelf Registration, Including $125M Nasdaq Common Stock ATM Offering Through TD Cowen
-SEC Filing